These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
917 related articles for article (PubMed ID: 32937045)
1. Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis. Furie R; Rovin BH; Houssiau F; Malvar A; Teng YKO; Contreras G; Amoura Z; Yu X; Mok CC; Santiago MB; Saxena A; Green Y; Ji B; Kleoudis C; Burriss SW; Barnett C; Roth DA N Engl J Med; 2020 Sep; 383(12):1117-1128. PubMed ID: 32937045 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Belimumab in Patients With Lupus Nephritis: Subgroup Analyses of a Phase 3 Randomized Trial in the East Asian Population. Yu X; Chen N; Xue J; Mok CC; Bae SC; Peng X; Chen W; Ren H; Li X; Noppakun K; Gilbride JA; Green Y; Ji B; Liu C; Madan A; Okily M; Tang CH; Roth DA Am J Kidney Dis; 2023 Mar; 81(3):294-306.e1. PubMed ID: 36058429 [TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of Belimumab in Patients with Lupus Nephritis: Open-Label Extension of BLISS-LN Study. Furie R; Rovin BH; Houssiau F; Contreras G; Teng YKO; Curtis P; Green Y; Okily M; Madan A; Roth DA Clin J Am Soc Nephrol; 2022 Nov; 17(11):1620-1630. PubMed ID: 36302567 [TBL] [Abstract][Full Text] [Related]
5. A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis. Rovin BH; Furie R; Teng YKO; Contreras G; Malvar A; Yu X; Ji B; Green Y; Gonzalez-Rivera T; Bass D; Gilbride J; Tang CH; Roth DA Kidney Int; 2022 Feb; 101(2):403-413. PubMed ID: 34560137 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Rovin BH; Teng YKO; Ginzler EM; Arriens C; Caster DJ; Romero-Diaz J; Gibson K; Kaplan J; Lisk L; Navarra S; Parikh SV; Randhawa S; Solomons N; Huizinga RB Lancet; 2021 May; 397(10289):2070-2080. PubMed ID: 33971155 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study. Mysler EF; Spindler AJ; Guzman R; Bijl M; Jayne D; Furie RA; Houssiau FA; Drappa J; Close D; Maciuca R; Rao K; Shahdad S; Brunetta P Arthritis Rheum; 2013 Sep; 65(9):2368-79. PubMed ID: 23740801 [TBL] [Abstract][Full Text] [Related]
9. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. Ginzler EM; Dooley MA; Aranow C; Kim MY; Buyon J; Merrill JT; Petri M; Gilkeson GS; Wallace DJ; Weisman MH; Appel GB N Engl J Med; 2005 Nov; 353(21):2219-28. PubMed ID: 16306519 [TBL] [Abstract][Full Text] [Related]
10. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE. Dooley MA; Houssiau F; Aranow C; D'Cruz DP; Askanase A; Roth DA; Zhong ZJ; Cooper S; Freimuth WW; Ginzler EM; Lupus; 2013 Jan; 22(1):63-72. PubMed ID: 23263865 [TBL] [Abstract][Full Text] [Related]
11. Comparison of Lupus Nephritis Induction Treatments in a Hispanic Population: A Single-center Cohort Analysis. Mejía-Vilet JM; Arreola-Guerra JM; Córdova-Sánchez BM; Morales-Buenrostro LE; Uribe-Uribe NO; Correa-Rotter R J Rheumatol; 2015 Nov; 42(11):2082-91. PubMed ID: 26373566 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study. Jayne D; Blockmans D; Luqmani R; Moiseev S; Ji B; Green Y; Hall L; Roth D; Henderson RB; Merkel PA; Arthritis Rheumatol; 2019 Jun; 71(6):952-963. PubMed ID: 30666823 [TBL] [Abstract][Full Text] [Related]
13. Combined immunosuppressive treatment (CIST) in lupus nephritis: a multicenter, randomized controlled study. An Y; Zhou Y; Bi L; Liu B; Wang H; Lin J; Xu D; Wang M; Zhang J; Wang Y; An Y; Zhu P; Xie R; Zhang Z; Mei Y; Liu X; Deng X; Yao Z; Zhang Z; Wang Y; Xiao W; Shen H; Yang X; Xu H; Yu F; Wang G; Lu X; Li Y; Li Y; Zuo X; Li Y; Liu Y; Zhao Y; Guo J; Sun L; Zhao M; Li Z Clin Rheumatol; 2019 Apr; 38(4):1047-1054. PubMed ID: 30488367 [TBL] [Abstract][Full Text] [Related]
14. Effect of belimumab on kidney-related outcomes in patients with lupus nephritis: post hoc subgroup analyses of the phase 3 BLISS-LN trial. Anders HJ; Furie R; Malvar A; Zhao MH; Hiromura K; Weinmann-Menke J; Green Y; Jones-Leone A; Negrini D; Levy RA; Lightstone L; Tanaka Y; Rovin BH Nephrol Dial Transplant; 2023 Nov; 38(12):2733-2742. PubMed ID: 37463054 [TBL] [Abstract][Full Text] [Related]
15. Phase III/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus. Ginzler E; Guedes Barbosa LS; D'Cruz D; Furie R; Maksimowicz-McKinnon K; Oates J; Santiago MB; Saxena A; Sheikh S; Bass DL; Burriss SW; Gilbride JA; Groark JG; Miller M; Pierce A; Roth DA; Ji B Arthritis Rheumatol; 2022 Jan; 74(1):112-123. PubMed ID: 34164944 [TBL] [Abstract][Full Text] [Related]
17. Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide. Contreras G; Tozman E; Nahar N; Metz D Lupus; 2005; 14 Suppl 1():s33-8. PubMed ID: 15803929 [TBL] [Abstract][Full Text] [Related]
18. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Liu Z; Zhang H; Liu Z; Xing C; Fu P; Ni Z; Chen J; Lin H; Liu F; He Y; He Y; Miao L; Chen N; Li Y; Gu Y; Shi W; Hu W; Liu Z; Bao H; Zeng C; Zhou M Ann Intern Med; 2015 Jan; 162(1):18-26. PubMed ID: 25383558 [TBL] [Abstract][Full Text] [Related]
19. Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis. Atisha-Fregoso Y; Malkiel S; Harris KM; Byron M; Ding L; Kanaparthi S; Barry WT; Gao W; Ryker K; Tosta P; Askanase AD; Boackle SA; Chatham WW; Kamen DL; Karp DR; Kirou KA; Sam Lim S; Marder B; McMahon M; Parikh SV; Pendergraft WF; Podoll AS; Saxena A; Wofsy D; Diamond B; Smilek DE; Aranow C; Dall'Era M Arthritis Rheumatol; 2021 Jan; 73(1):121-131. PubMed ID: 32755035 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of belimumab combined with the standard regimen in treating children with lupus nephritis. Li H; Chen C; Yang H; Tu J Eur J Pediatr; 2024 Sep; 183(9):3987-3995. PubMed ID: 38940925 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]